In this webinar, Steven C. Katz, M.D., FACS, Chief Medical Officer at TriSalus Life Sciences, leads a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-02) clinical trial for adults with intrahepatic cholangiocarcinoma and hepatocellular carcinoma, the most common primary liver tumors. Dr. Katz is joined by Venu Pillarisetty, M.D., Professor of Hepatopancreatobiliary Surgery at the University of Washington and Medical Director of Continuous Performance Improvement at Seattle Cancer Care Alliance and Karie Runcie, M.D., Assistant Professor of Medicine at Columbia University Herbert Irving Comprehensive Cancer Center
The PERIO-02 trial is evaluating SD-101, an investigational toll-like receptor 9 (TLR9) agonist, delivered intravascularly by the TriNav Infusion System using the Pressure-Enabled Drug Delivery (PEDD) method of administration. The study objective is to understand the ability of this platform to overcome two major challenges of treatment: immune response suppression and ineffective drug delivery.
Recorded on January 13, 2022